U-BIOPRED: evaluation of the value of a public-private partnership to industry.
Drug Discov Today
; 23(9): 1622-1634, 2018 09.
Article
em En
| MEDLINE
| ID: mdl-29936248
ABSTRACT
Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) was initiated in the first year of the Innovative Medicines Initiative (IMI). It was an ambitious plan to tackle the understanding of asthma through an integration of clinical and multi-'omics approaches that necessitated the bringing together of industry, academic, and patient representatives because it was too large to be managed by any one of the partners in isolation. It was a novel experience for all concerned. In this review, we describe the main features of the U-BIOPRED experience from the industry perspective. We list some of the key advantages and learnings from the perspective of the authors, and also improvements that we feel could be made in future projects.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Biomarcadores
/
Antiasmáticos
/
Indústria Farmacêutica
/
Descoberta de Drogas
/
Parcerias Público-Privadas
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Guideline
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article